Clinical Trials Browser

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Recurrence

NCT06342986 2026-04-02

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Phase 1 Active not recruiting

3 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05922930 2026-02-19

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

Phase 1/2 Recruiting

51 enrolled

GastrointestinalGynecologic

Adenocarcinoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT07410494 2026-02-18

SELECT-CAR-NK

Phase 1/2 Recruiting

85 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1 Withdrawn

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04670068 2025-12-22

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

Phase 1 Active not recruiting

4 enrolled 8 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT02869217 2025-12-03

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

Phase 1 Active not recruiting

22 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT03449108 2025-11-21

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Phase 2 Active not recruiting

30 enrolled

BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05225363 2025-07-01

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

Phase 1 Recruiting

33 enrolled

Gynecologic

Platinum-Resistant Ovarian Carcinoma

NCT03610490 2025-04-17

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Phase 2 Terminated

16 enrolled 11 charts

GastrointestinalGynecologic

Ovarian Neoplasms, Colorectal Neoplasms

NCT06825455 2025-02-13

Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors

Phase EARLY_PHASE1 Not yet recruiting

18 enrolled

Gynecologic

Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms

NCT06630611 2025-01-28

PragmaTIL

Phase 2 Recruiting

40 enrolled

DermatologicGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma

NCT03287674 2023-03-01

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

Phase 1/2 Completed

7 enrolled 10 charts

Gynecologic

Ovarian Neoplasms

NCT03814447 2021-08-10

The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer

Phase EARLY_PHASE1 Unknown

10 enrolled

Gynecologic

Ovarian Neoplasms

NCT02096614 2021-06-18

Investigator Initiated Phase 1 Study of TBI-1201

Phase 1 Completed

18 enrolled

DermatologicGastrointestinalGynecologicHead & Neck

Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms

NCT01312376 2020-04-24

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

Phase 1 Terminated

18 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03916679 2019-04-16

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

Phase 1/2 Unknown

20 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT03799913 2019-04-10

MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer

Phase EARLY_PHASE1 Unknown

20 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT02366546 2018-10-24

Investigator Initiated Phase 1 Study of TBI-1301

Phase 1 Unknown

9 enrolled

DermatologicGastrointestinalGynecologicHead & NeckSarcoma

Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT00652899 2017-12-28

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Phase 2 Terminated

14 enrolled 9 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01105650 2017-12-28

MT2009-30

Phase 2 Completed

13 enrolled 11 charts

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02118285 2017-12-05

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Phase 1 Completed

2 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03335241 2017-11-13

Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer

Phase 2 Unknown

140 enrolled

Gynecologic

Ovarian Neoplasms

NCT02482090 2017-08-16

TIL Therapy for Metastatic Ovarian Cancer

Phase 1 Completed

6 enrolled

Gynecologic

Ovarian Neoplasms

NCT02457650 2016-08-03

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Phase 1 Unknown

36 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT00523809 2013-01-28

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

Phase 2 Terminated

5 enrolled 4 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

Clinical Trials

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

SELECT-CAR-NK

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors

PragmaTIL

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer

Investigator Initiated Phase 1 Study of TBI-1201

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer

Investigator Initiated Phase 1 Study of TBI-1301

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

MT2009-30

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer

TIL Therapy for Metastatic Ovarian Cancer

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor